Genpharmasec Limited reported a standalone net profit of ₹156.96 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a slight increase from ₹155.92 lakh in the corresponding period of FY26. The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in Mumbai. While the standalone entity remained profitable, the group’s consolidated position turned negative, reporting a net loss of ₹17.37 lakh for the quarter, primarily driven by losses attributable to non-controlling interests.

The filing was made pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subsequently approved by the Board. Bilimoria Mehta & Co., Chartered Accountants, served as the independent auditors, issuing an unmodified review report. The audit committee reviewed the financial statements on August 11, 2026, before they were tabled before the Board.

Financial Performance Overview

On a standalone basis, revenue from operations rose significantly to ₹4,478.44 lakh in Q1FY27, up from ₹1,211.32 lakh in Q1FY26. Total income reached ₹4,575.50 lakh, supported by other income of ₹97.06 lakh. Expenses totaled ₹4,365.78 lakh, with purchase of stock-in-trade accounting for ₹4,530.97 lakh, partially offset by a decrease in inventories of ₹249.05 lakh. Profit before tax stood at ₹209.72 lakh, against a tax expense of ₹52.76 lakh.

Consolidated revenue from operations was ₹4,971.03 lakh, compared to ₹1,204.32 lakh in the previous year’s quarter. However, total expenses were higher at ₹4,982.57 lakh, leading to a profit before tax of only ₹25.77 lakh. After a total tax expense of ₹43.13 lakh, the group reported a net loss of ₹17.37 lakh. This contrasts with a consolidated net profit of ₹121.52 lakh in Q1FY26.

Segment-wise Analysis

The Pharmaceuticals segment contributed ₹4,478.44 lakh to revenue and generated a segment result (profit before tax and interest) of ₹222.41 lakh. The Manufacturing & Processing segment reported revenue of ₹271.92 lakh but incurred a segment loss of ₹125.07 lakh. The Laboratory Testing segment posted a loss of ₹29.20 lakh with no reported revenue for the quarter. Unallocable items accounted for ₹220.67 lakh in revenue and a minor loss of ₹2.45 lakh.

Total segment assets increased to ₹15,628.35 lakh from ₹13,815.34 lakh in the preceding quarter. Segment liabilities rose to ₹9,064.44 lakh from ₹7,250.86 lakh. The Pharmaceuticals segment held the largest share of assets at ₹6,918.07 lakh and liabilities at ₹3,936.34 lakh.

What the Numbers Show

A divergence exists between the standalone profitability and the consolidated loss position. While the parent company reported a stable net profit, the consolidated loss of ₹17.37 lakh was largely driven by non-controlling interests, which attributed a loss of ₹43.34 lakh to the group. This suggests that subsidiaries or joint ventures may be facing operational challenges that are not reflected in the parent company’s direct operations. Additionally, the Laboratory Testing and Manufacturing & Processing segments continued to report losses, indicating ongoing pressure in these business lines despite strong performance in Pharmaceuticals.

Genpharmasec Limited has reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results during a meeting held on May 21, 2026. The company published an extract of these results in newspapers Active Times and Mumbai Lakshadeep on May 23, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

For the financial year 2026, the company recorded a standalone net profit of ₹544.96 lakh, a significant increase from the ₹280.04 lakh reported in the previous year. Revenue from operations for the year surged to ₹13,134.94 lakh, up from ₹3,296.07 lakh in the prior year. For the quarter ended March 31, 2026, the company posted a net profit of ₹231.81 lakh on revenue of ₹5,166.42 lakh. The statutory auditors, M/s. Bilimoria Mehta & Co., issued an audit report with an unmodified opinion on the standalone and consolidated financial results.

Financial Performance

The company's total income for the year stood at ₹13,621.88 lakh, compared to ₹3,639.16 lakh in the previous year. Total expenses for the period were ₹12,978.19 lakh. Profit before tax for the year was ₹643.69 lakh, while the tax expense was recorded at ₹98.72 lakh.

Consolidated Results

On a consolidated basis, the company reported a net profit of ₹56.01 lakh for the year ended March 31, 2026, compared to ₹156.28 lakh in the previous year. Consolidated revenue from operations for the year was ₹13,993.77 lakh. The auditors noted material uncertainties regarding the going concern status of two subsidiaries, Derren Healthcare Private Limited and Clinigenome India Private Limited, due to losses and erosion of net worth. However, the financial statements were prepared on a going concern basis based on management plans and financial support from the holding company.

Board Decisions

Alongside the financial results, the Board approved the re-appointment of M/s. Abhishek M Agrawal & Co., Chartered Accountants, as the Internal Auditor of the company for the financial year 2026-27. The appointment is pursuant to Section 138 of the Companies Act, 2013. The Board also confirmed that the Statutory Auditors' report carries an unmodified opinion.